Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEGIN: BB T1 LONG
NCT00982228Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2009
- Primary completion
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of insulin degludec in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Change in Glycosylated Haemoglobin at 52 weeks, Rate of Treatment Emergent Adverse Events at 104 weeks and 2 more. Started Sep 2009; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00982228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00982228.